中心组合设计-效应面法优化曲安奈德固体脂质纳米粒处方

Optimization of Triamcinolone Acetonide-loaded Solid Lipid Nanoparticles Formula by Central Composite Design and Response Surface Methodology

关键词:  中心组合设计  曲安奈德  固体脂质纳米粒  高温乳化-低温固化法

Key words:  central composite design  triamcinolone acetonide  solid lipid nanoparticles  emulsion evaporation at a high temperature and solidification at a low temperature

摘要:

目的 采用中心组合设计-效应面法优化曲安奈德固体脂质纳米粒(TACA-SLN)的处方。方法 采用中心组合设计-效应面优化法筛选处方，以曲安奈德包封率作为评价指标，考察泊洛沙姆188的浓度，单硬脂酸甘油酯和大豆卵磷脂的质量比，药物和脂质材料的质量比，水相和有机相的体积比对评价指标的影响。采用高温乳化-低温固化法制备TACA-SLN。结果 优选的最佳处方为：泊洛沙姆188浓度1.89%，单硬脂酸甘油酯与大豆卵磷脂质量比1.95，药物与脂质质量比0.15，水相与油相体积比5.68，实验值与理论值偏差0.07%。结论 中心组合设计-效应面法能有效优选TACA-SLN处方。

Abstract:

OBJECTIVE To optimize the formula of triamcinolone acetonide-loaded solid lipid nanoparticles(TACA-SLN). METHODS Central composite design and response surface methodology was applied to screen TACA-SLN prescription. The influence factors such as F68 concentration, the ratio of glyceryl monostearate to lecithin, the ratio of drug to lipids, the ratio of water phase to organic phase were investigated using entrapment efficiency as evaluation parameter. TACA-SLN was prepared by the method of emulsion evaporation at a high temperature and solidification at a low temperature. RESULTS The optimum prescription was: F68 1.89%, the ratio of glyceryl monostearate to lecithin was 1.95, the ratio of drug to lipids was 0.15, the ratio of water phase to organic phase was 5.68. The bias was 0.07%. CONCLUSION Cental composite design and response surface metogology was successfully used to optimize the formulation of TACA-SLN.